In the BioHarmony Drug Report Database

"Preview" Icon

Talimogene laherparepvec

Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-12-16. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.

 

Trade Name

 

Imlygic
 

Common Name

 

talimogene laherparepvec
 

ChEMBL ID

 

CHEMBL2108727
 

Indication

 

melanoma
 

Drug Class

 

Image (chem structure or protein)

Talimogene laherparepvec structure rendering